United Therapeutics Executive and Leadership Team

Harsh Hurkat, the Senior Analyst - Chief Financial Officer Org at United Therapeutics, manages financial modeling and capital allocation strategies for the biotechnology portfolio. Overseeing budgetary planning for research and development initiatives, the Senior Analyst - Chief Financial Officer Org ensures fiscal discipline across all therapeutic programs. This leadership role involves analyzing market trends to support strategic investment decisions in advanced medical technologies. By evaluating the financial viability of new pharmaceutical projects, Harsh Hurkat directly impacts the company's ability to address unmet medical needs. Furthermore, the Senior Analyst - Chief Financial Officer Org provides critical data insights to the executive team to facilitate informed decision-making regarding global market expansion. Through rigorous financial oversight, Hurkat maintains the economic stability required to sustain long-term development cycles for life-threatening disease treatments.

Jeff Ross, the President, Miromatrix at United Therapeutics, leads the development and commercialization of advanced organ manufacturing technologies. Overseeing the integration of bioengineering breakthroughs into the broader corporate pipeline, the President, Miromatrix ensures alignment with the mission to solve critical organ shortages. This leadership role involves managing complex manufacturing processes and scaling production capabilities to meet global demand for regenerative medicine. By driving innovation in tissue engineering, Jeff Ross directly impacts the company's capacity to provide life-saving solutions for patients with end-stage organ failure. Furthermore, the President, Miromatrix coordinates with research teams to translate experimental therapies into viable clinical applications. Through the advancement of proprietary organ manufacturing platforms, Ross establishes a new standard for medical intervention in chronic disease management.

Jeffrey Kase, the Vice President, Chief Information Officer at United Therapeutics, directs the digital infrastructure supporting complex biotechnology research and manufacturing operations. Overseeing enterprise-wide data security and systems architecture, the Vice President, Chief Information Officer ensures seamless integration between laboratory research platforms and commercial distribution networks. This leadership role involves implementing scalable cloud solutions to accelerate drug discovery timelines across North American research facilities. By optimizing internal data workflows, Jeffrey Kase directly impacts the efficiency of clinical trial management and regulatory compliance reporting. Furthermore, the Vice President, Chief Information Officer collaborates with executive leadership to align technological investments with long-term corporate growth objectives. Through the modernization of digital assets, Kase secures the integrity of sensitive patient information while fostering a robust environment for innovation in rare disease treatment development.

Alyssa Friedrich, the Executive Vice President & Chief People Officer at United Therapeutics, directs human capital strategy and organizational development for the biotechnology workforce. Overseeing talent acquisition and employee engagement initiatives, the Executive Vice President & Chief People Officer ensures the company attracts top-tier scientific and operational expertise. This leadership role involves fostering a culture of innovation that supports the discovery and manufacturing of rare disease therapies. By implementing comprehensive professional development programs, Alyssa Friedrich directly impacts the retention of specialized talent necessary for complex pharmaceutical operations. Furthermore, the Executive Vice President & Chief People Officer collaborates with the Board to align workforce capabilities with the evolving needs of the global healthcare market. Through the cultivation of a high-performance environment, Friedrich sustains the organizational momentum required to deliver life-changing medical technologies.